House Ways and Means Health Subcommittee will make Medicare prescription drug benefit oversight priority in 2007

NewsGuard 100/100 Score

The House Ways and Means Subcommittee on Health will examine oversight of the Medicare prescription drug benefit among other priorities for the 110th Congress, House Ways and Means Committee Chair Charles Rangel (D-N.Y.) and ranking member Jim McCrery (R-La.) wrote in a letter sent last Wednesday to leaders of the House Oversight and Government Reform Committee and the House Administration Committee, CQ HealthBeat reports.

The subcommittee will examine prices for medications under the Medicare prescription drug benefit, as well as proposals to establish a "Medicare-sponsored drug option" and "negotiated price mechanisms," according to the letter.

In addition, the subcommittee will examine the relationship between Medicare reimbursement policies and workforce concerns, the adequacy of benefits and competitive bidding for durable medical equipment.

The subcommittee also will examine oversight of the Medicare "trigger," the point at which federal general revenue contributions account for 45% of total Medicare spending, and oversight of "budget and staffing, contracting activities" and accountability at CMS, the letter states.

In addition to Medicare issues, the subcommittee will examine health savings accounts and proposals to expand health insurance for children, early retirees and small business employees (Carey, CQ HealthBeat, 1/18).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Increased drug coverage restrictions in Medicare Part D raises concerns